Sunshine Heart Provides Corporate Update EDEN PRAIRIE,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sunshine Heart Provides Corporate Update

EDEN PRAIRIE, Minn., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq: SSH ) today provided an update on the Company's U.S. Counter HF™ and European OPTIONS HF studies along with progress on its next generation, fully implantable C-Pulse ® Heart Assist System.

The U.S. Counter HF study concluded 2014 with 40 enrollments, 21 activated centers, and 12 additional centers committed to participate. The Company is pleased to report 13 patients were enrolled in the fourth quarter, which was much higher than projected. In addition, despite challenges during the quarter presented by seasonality, the company continued to experience strong site enthusiasm in identifying potential patients. 15 of the 21 activated centers have enrolled patients with 2 new centers enrolling their first patient. Moving forward, Sunshine Heart is expecting to experience continued growth in enrollment throughout 2015 due to the following: Addition of 2 development therapy specialists (5 total) to accelerate patient enrollment, increased site proficiency in identifying appropriate patients, continued site activations. Furthermore, the Company expects a decision from the FDA on its request to conduct an interim analysis before the end of the first quarter of 2015. If successful in demonstrating efficacy at the time of interim analysis, the Company will be in a position to discuss early PMA submission with FDA. Data was also obtained during device optimization using pulse wave analysis by the AtCor Medical Sphygmograph. Key metrics typically used to determine the impact on left ventricular load are: left ventricular (LV) wall stress, LV stroke volume, Wasted Energy (W E ), Tension-Time Index (TTI). Sunshine Heart has published data on the positive effects of C-Pulse on LV stroke volume and wall stress. Recent evaluation of this data demonstrated improvements in reduction of Wasted Energy and Tension-Time index, two key metrics in evaluating myocardial oxygen consumption. These measurements were taken with the C-Pulse system turned-off and then measured once it had been reactivated. These metrics have also been used to assess cardiac resynchronization therapy success.

With respect to the European OPTIONS HF study, Sunshine Heart finished 2014 with 14 implants performed of which two implants were completed in the fourth quarter at newly activated sites in Germany and Austria. The Company expects to see continued growth in European implants in the first quarter of 2015 and beyond and expects to release study results in mid-2016. A response from the German authorities regarding Sunshine Heart's New Diagnostic and Methods (NUB) submission for reimbursement for the C-Pulse System is expected in February. Given that the Company has not built any revenue in its 2015 plan for EU reimbursement, an approval would represent financial upside to internal guidance. The Company currently has direct representation in Europe to provide clinical and future sales support for the OPTIONS HF trial and commercial purposes.

"We are particularly pleased with progress achieved during the fourth quarter with both of the COUNTER HF™ and OPTIONS HF trials. The pace of enrollment in both studies seems to be gaining sustainable momentum and we will continue to provide updates along the way when appropriate," commented Dave Rosa, Chief Executive Officer of Sunshine Heart.

On the research and development front, the next generation, fully implantable C-Pulse System continues to experience exciting progress. During the course of 2014, Sunshine Heart successfully completed both acute and chronic animal trials and has already developed its next, smaller iteration which the Company's physician advisors are confident can be placed via a minimally invasive procedure. Sunshine Heart has also built in-house expertise in the software and hardware components of the C-Pulse System through additional personnel hires to complement independent partners helping with the development of the C-Pulse pump and TETS (Transcutaneous Energy Transfer System). With continued progress, the Company believes it is well positioned to be the first current mechanical assist company to complete its first in man clinical evaluation.  The Company is currently scheduled to meet with the FDA to discuss the fully implantable system on January 15, 2015.

About the C-Pulse ® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine ® Heart

Sunshine Heart, Inc. (Nasdaq: SSH ) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure.  Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011.  In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application.  Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial.  In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe.  Sunshine Heart is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly-owned subsidiaries in Australia and Ireland.  The Company has been listed on the NASDAQ Capital Market since February 2012.  

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management.  All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical trial activities and results including patient enrollment in trials. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the U.S. Securities and Exchange Commission.  You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Investor: Candice Knoll Blueprint Life Science Group T: +1-415-375-3340 Ext. 105 Claudia Drayton Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4200 Media: David Schull Russo Partners T: +1-212-845-4271

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 49

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 205

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 113

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 68

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 89

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 19

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 142

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Updated Category News Views 131

Avicanna's 5th Medical Symposium on Cannabinoid Medicine On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and...

Continue Reading
Gordian's Exciting New Initiative for Public Facility Planning

Updated Category News Views 277

Gordian's New Sourcewell Contract Gordian, a well-known provider of data-driven solutions for various phases of the building lifecycle, has recently secured a significant contract with Sourcewell. This partnership will broaden Gordian’s offerings to numerous government and educational organizations eager to enhance their facility planning capabilities. Facilitating...

Continue Reading
Paramount Global CFO Transition: A New Era Begins

Updated Category News Views 251

Paramount Global Announces Significant Leadership Change Paramount Global (NASDAQ: PARA) has made a noteworthy announcement regarding its executive leadership. Naveen Chopra, who has been serving as the Chief Financial Officer and Executive Vice President, will be departing from the company to explore new opportunities. The company's Board of Directors has stated that...

Continue Reading
Explore the Potential of Axsome, CRISPR, and Pfizer Stocks

Updated Category News Views 134

Back in 2023, the stock market was a mixed bag, with plenty of sectors showing serious signs of overvaluation. You had legends like Warren Buffett sitting on a mountain of cash, clearly indicating he saw overpriced stocks everywhere. When seasoned investors hit the brakes on buying due to high valuations, it’s like an alarm bell for everyone else—caution was in the...

Continue Reading
Boeing's Production Delays and Its Impact on Suppliers

Updated Category News Views 245

A Closer Look at Boeing's Production Setbacks Boeing Co has recently notified its suppliers about a significant change to a key production milestone for its 737 MAX aircraft. This adjustment, which extends the timeline by six months, has raised concerns within the aviation industry. Sources indicate that the new objective is to achieve an output of 42 jets per month by...

Continue Reading